Posted by Michael Wonder on 29 Mar 2023
Libtayo (cemiplimab) in combination with chemotherapy approved by European Commission for the first-line treatment of advanced PD-L1 positive non-small-cell lung cancer
29 March 2023 - Approval marks second first-line indication in non-small-cell lung cancer and fifth indication for Libtayo in the European Union.
Regeneron Pharmaceuticals today announced that the European Commission approved Libtayo (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small-cell lung cancer with ≥1% PD-L1 expression.
